NCLAT: Can’t Dismiss Restoration App. if Filed in 30 Days from Date of Dismissal of Original App. || Delhi HC: Communication between Parties through Whatsapp Constitute Valid Agreement || Delhi HC Seeks Response from Govt. Over Penalties on Petrol Pumps Supplying Fuel to Old Vehicles || Centre Notifies "Unified Waqf Management, Empowerment, Efficiency and Development Rules, 2025" || Del. HC: Can’t Reject TM Owner’s Claim Merely because Defendant Could have Sought Removal of Mark || Bombay HC: Cannot Treat Sole Director of OPC, Parallelly with Separate Legal Entity || Delhi HC: Can Apply 'Family of Marks' Concept to Injunct Specific Marks || HP HC: Can’t Set Aside Ex-Parte Decree for Mere Irregularity || Cal. HC: Order by HC Bench Not Conferred With Determination by Roster is Void || Calcutta HC: Purchase Order Including Arbitration Agreement to Prevail Over Tax Invoice Lacking it

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :